Towards Stratified Medicine in Plasma Cell Myeloma.

doi:10.3390/ijms17101760

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Towards Stratified Medicine in Plasma Cell Myeloma.

International journal of molecular sciences - 21 Oct 2016

Egan Philip, Drain Stephen, Conway Caroline, Bjourson Anthony J, Alexander H Denis

Abstract excerpt

Plasma cell myeloma is a clinically heterogeneous malignancy accounting for approximately one to 2% of newly diagnosed cases of cancer worldwide. Treatment options, in addition to long-established cytotoxic drugs, include autologous stem cell transplant, immune modulators, proteasome inhibitors and monoclonal antibodies, plus further targeted therapies currently in clinical trials. Whilst treatment decisions are...

Topics

Biomarkers, Tumor
Disease Progression
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Humans
Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Neoplasm Recurrence, Local
Neoplasm, Residual
Outcome Assessment, Health Care

Source

Open in PubMed Open full text

Identifiers

PMID: 27775669
DOI: 10.3390/ijms17101760
PMCID: PMC5085784

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics